The company said over 10 emerging markets along with Japan, Australia and New Zealand have transitioned in this final phase of the integrat...

Biocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...

BBL said the cash payment of $2 billion to be funded by $800 million raised through equity infusion in BBL and the remainder to be funded b...

Lupin’s Pune facility is known for its R&D and manufacturing work related to biosimilars.

"Looking ahead, FY2020 is an exciting year for Lupin as we plan to bring our first biosimilar to market," company said.

Biosimilar Etanercept is used to fight a range of severe auto-immune disorders.

Biosimilars are approved versions of biopharmaceuticals — complex medicines manufactured using live organisms, as against conventional drug...

Biocon and Mylan have been working for a decade on a biosimilar version of the drug, originally sold by Amgen under brand name Enbrel.

Under the terms of the agreement, Lupin will receive an up-front payment of $15 million and potential commercial milestones together with a...

It takes 12-13 months for the Japanese drug authorities to give product approvals.

Mumbai based Lupin pharma and Japan's Nichi-Iko have tied up for the distribution, promotion and sale of Lupin’s recently-filed biosimilar ...

The randomised trial of 52 weeks was conducted in 11 countries and included over 500 patients, Lupin said.

Lupin's Etanercept biosimilar, developed by its Biotechnology Research Group in Pune will be the first product to be licensed for clinical ...

Biocon today said it has received approval from the Indian drug regulator to market its biosimilar trastuzumab developed jointly with Mylan.

Biocon said it has received approval to market its biosimilar trastuzumab developed jointly with Mylan for treating breast cancer.

A lobby group of biotech drug companies in India has raised concerns about the approval of Cipla's first biosimilar drug Etanercept.

Drug major Cipla said it has launched biosimilar of Etanercept under the brand name 'Etacept' used for treatment of rheumatic disorders in ...